Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 25/2/2021
SIETES contiene 93212 citas

 1 a 12 de 12 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:28 de septiembre. [Ref.ID 102096]
2.Tiene citas relacionadas
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, Demets D, Evans S, Law M, McMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercok P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61. [Ref.ID 100988]
3.Tiene citas relacionadas Cita con resumen
Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompoint S, Billot L, Rodgers A, UMPIRE Collaborative Group. Effects of a fixed -dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918-29. [Ref.ID 96053]
4. Cita con resumen
Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, MacMahon SC, Cooper ME, Hamet P, Marre M, Mogensen CE, Poulter N, Mancia G, Cass A, Patel A, Zoungas S. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013;83:517-23. [Ref.ID 95115]
5.Enlace a cita original
Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S, Hamet P, Poulter N, Lip GYH, Patel A, on behalf of the ADVANCE Collaborative Group. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30:1128-35. [Ref.ID 85434]
6.Tiene citas relacionadas Cita con resumen
Dahlöf B, Sever P, Poulter N, Wedel H, for the ASCOT Investigators. ASCOT-BPLA. Authors' reply. Lancet 2006;367:207-8. [Ref.ID 75992]
7. Cita con resumen
Wilson S, Johnston A, Robson J, Poulter N, Collier D, Feder G, Caulfield MJ. Comparison of methods to identify individuals at increased risk of coronary disease from the general population. BMJ 2003;326:1436-8. [Ref.ID 66652]
8.Tiene citas relacionadas
Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363-9. [Ref.ID 66311]
9.Tiene citas relacionadas Cita con resumen
Sever PS, Dahlöf B, Poulter N, Wedel H, on behalf of the ASCOT Steering Committee and Investigators. ASCOT-LLA: questions about the benefits of atorvastatin. Authors' reply. Lancet 2003;361:1986-7. [Ref.ID 66180]
10. Cita con resumen
Wimalasundera RC, Larbalestier N, Smith JH, De Ruiter A, Thom SAM, Hughues AD, Poulter N, Regan L, Taylor GP. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002;360:1152-4. [Ref.ID 63635]
11.Tiene citas relacionadas
Poulter N, Alberti KGMM, Beevers DG, Betteridge DJ, Campbell RWF. Drug therapy for coronary heart disease: the Sheffield table. Authors' reply. Lancet 1998;351:443-4. [Ref.ID 42649]
12. Cita con resumen
Chang CL, Donaghy M, Poulter N, and World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. BMJ 1999;318:13-8. [Ref.ID 42315]
Seleccionar todas
 1 a 12 de 12